Pancuronium bromide, a bisquaternary amino-required to maintain muscular relaxation after steroid described by Buckett, Hewett and Savage intubation with suxamethonium. (1967) , has been shown to be a potent neuromuscular blocking agent with only minimal gang-METHOD lion-blocking and histamine-releasing properties The fifteen patients studied were adult in-patients (Buckett et al., 1968) . These qualities make it a undergoing routine surgery under general anaesvaluable drug, particularly in poor-risk patients thesia. All were free from cardiorespiratory and in patients with an allergic diathesis (Me-disease. The age, weight and sex of each patient, Dowell and Clarke, 1969; Stojanov, 1969) .
together with the dose of premedicant and inIn the present study we have investigated the duction agent used are shown in table I. All effects of pancuronium bromide on the human patients had consented to the investigation. cardiovascular system. The dose used (0.07 mg/kg -body weight) was selected as being intermediate G. R. KELMAN Premedication in all patients was with papaveretum, 15 or 20 mg depending on body weight, together with hyoscine 0.4 mg, given intramuscularly 60 minutes before induction of anaesthesia with thiopentone (250-400 mg). Tracheal intubation was performed under suxamethonium-induced muscular relaxation. Continued apnoea was then produced with phenoperidine (1 mg/15 kg), and controlled ventilation maintained (60 per cent nitrous oxide in oxygen) with a Manley ventilator and non-rebreathing circuit. End-tidal Pco, was monitored continuously with an infra-red carbon dioxide analyzer (URAS 3, Hartmann and Braun). The ventilatory minute volume was adjusted to maintain the end-expired Pco 3 at 30 ± 2 rnm Hg.
All measurements of heart rate, arterial blood pressure and cardiac output were made before the start of surgery. Control measurements were made at 17 and 19 minutes after induction of anaesthesia. The patients were then given either no drug (5 patients) or (10 patients) pancuronium bromide, 0.07 mg/kg body weight intravenously. The cardiovascular measurements were then repeated after 2, 5 and 10 minutes.
Heart rate was measured from an e.c.g. tracing, which was also scrutinized for the occurrence of arrhythmias. Arterial blood pressure (systolic and diastolic) was measured with a sphygomanometer; the mean pressure was assumed to be diastolic pressure plus one-third pulse pressure. Changes in cardiac output were estimated by the indicator dilution technique with indocyanine green and a Waters XE 302 photoelectric earpiece and associated electronic equipment. The dye curves were not calibrated. The object was to measure the changes of cardiac output induced by pancuronium; non-calibrated dye curves are sufficient for this purpose (Gabe, Tuckman and Shillingford, 1962) and avoid the necessity for arterial puncture.
RESULTS
The initial values of mean arterial blood pressure and heart rate were comparable for the patients who received pancuronium and for those who received no drug (table II) .
The effects of pancuronium on heart rate, cardiac output, cardiac stroke volume, mean arterial blood pressure and total peripheral resistance (calculated by dividing mean arterial blood pressure by cardiac output) are shown in table HI. All results are expressed as percentage change from the pre-drug value, i.e. the state 20 minutes after induction of anaesthesia.
TABLE II
Actual mean arterial blood pressures and heart rales before the injection of pancuronium (or no drug in the control patients). Pancuronium caused a marked increase of heart rate (22-26 per cent), accompanied by lesser increases of cardiac output (6-9 per cent) and of mean arterial blood pressure (8-9 per cent). These changes were all statistically significant, although the effect on cardiac output was only just so (P<0.05 at 2 min). Calculated total peripheral resistance was unchanged from its value before the administration of pancuronium. There was no physiologically important change of any cardiovascular parameter in the five patients who received no drug, although there was, in fact, a small, statistically significant decrease of heart rate at 5 and 10 minutes.
DISCUSSION
The advantages of our technique for studying the cardiovascular effects of muscle relaxants have been discussed in a previous paper (Kennedy and Kelman, 1970) . In the present study, as in previous investigations, we have avoided the effects of surgical stimulation, and have maintained the arterial Pco 2 constant at a level typically found during artificial ventilation of anaesthetized patients.
The present investigation is, to our knowledge, the only study of the effects of pancuronium on cardiac output in man, although this has been investigated in dogs by Smith, Proctor and Spence (1970) .
Previous studies of the effects of pancuronium on heart rate and arterial blood pressure in man have been conflicting. Baird and Reid (1967) found that it had little effect on arterial blood pressure and heart rate; McDowell and Clarke (1969) showed that it had little effect on heart rate and caused a slight, and statistically insignificant, fall of arterial blood pressure. Conversely, Loh (1970) found that, in a dose of 0.12 mg/kg, pancuronium caused increases of both heart rate and of mean arterial blood pressure, results similar to those reported here. Loh's study is, however, not strictly comparable to the present investigation, because his patients were digitalized, no attempt was made to control their arterial PcOj, and the measurements were made after the start of surgery.
The most likely explanation for this discrepancy is the fact that the patients investigated by Baird and Reid (1967) and by McDowell and Clarke (1969) had been premedicated with atropine (0.6 mg), whereas those studied by Loh and by ourselves were premedicated with hyoscine in a dose (0.4 mg) which is generally considered to cause less vagal paralysis than 0.6 mg of atropine. Animal studies by Bonta, Goorissen and Derkx (1968) suggest that pancuronium reduces the effects of vagal stimulation on the heart; it might therefore be expected to cause an increase of heart rate and cardiac output, particularly in the presence of marked vagal activity. If this is the mechanism by which it acts in man, pancuronium would be expected to cause less increase of heart rate in patients whose cardiac efferent vagal pathways had already been partially blocked by atropine.
We have investigated the effects of pancuronium bromide in three patients anaesthetized in an identical manner to that described above, except that they had been premedicated with atropine (0.6 mg) rather than with hyoscine. Their mean heart rate before the injection of pancuronium was 82 beats/min (cf. 58 beats/min in the present study). The increase of heart rate in these patients was only 8 per cent, while the increases of mean arterial blood pressure and of cardiac output were only 3 per cent and 5 per cent, respectively. This finding strongly supports the hypothesis outlined in the previous paragraph.
The fact that pancuronium has no significant effect on the calculated total peripheral resistance suggests that this drug has little or no ganglionblocking activity. This is in keeping with the finding of Buckett and associates (1968) that the ganglion-blocking activity of pancuronium on the guineapig ileum and on the cat nictitating membrane is much less marked than that of hexamethonium.
EFFETS CARDIO-VASCULAIRES DU PANCURONIUM CHEZ L'HOMME

SOMMAIRE
Nous avons itudii les effets du bromure de pancuronium (administri a la dose de 0,07 mg/kg de poids corporel) sur la frequence cardiaque, la pression art^rielle moyenne, le debit cardiaque et la resistance periphirique totale (evaluee indirectement par calcul) chez dix malades soumis a une respiration assisted et anesthesias a l'aide de protoxyde d'azote a 60% dans de l'oxygene, avec administration de phenopendine (a raison de 1 mg/15 kgs de poids corporel) en plus. La tension en gaz carbonique Pco, a la fin de l'ondee respiratoire a 6t£ maintenue constante a un niveau de 30 ± 2 mm Hg. 
EFECTOS CARDIOVASCULARES DEL PANCURONIO EN EL HOMBRE
RESUMEN
Hemos investigado los efectos del bromuro de pancuronio (0,07 mg/kg peso corporal) sobre la frecuencia cardlaca, presidn sanguinea arterial media, rendimiento cardiaco y resistencia periferica total calculada en diez pacientes ventilados artificialmente, anestesiados con 6xido nitroso al 60 por ciento en oxigeno mas fenoperidina (1 mg/15 kg peso corporal). La Pco, ventilatoria final fue mantenida constante a 30±2 mm Hg. Hubo un marcado incremento estadisticamente significativo de la frecuencia cardiaca de aproximadamente el 25 por ciento, acompanado por incrementos menores, pero todavia estadisticamente significativos, del rendimiento cardiaco y presi6n sanguinea arterial media. La resistencia periferica total no fue modificada, lo cual indica que el pancuronio tiene poca actividad bloqueadora ganglionar.
